The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 353:1591-1603 October 13, 2005 Number 15
NextNext

Advances in Malignant Mesothelioma
Bruce W.S. Robinson, M.D., and Richard A. Lake, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum.1 This tumor was once rare, but its incidence is increasing worldwide, probably as a result of widespread exposure to asbestos, a factor with which it is associated (Table 1).8 There is substantial interest in this disease on the part of the medical community and the general public, because millions of people have been exposed to asbestos fibers, and many articles about the dangers of asbestos have appeared in the press.

View this table:
[in this window]
[in a new window]
 
Table 1. Worldwide Trends in the Epidemiologic Features of Malignant Mesothelioma.

 
In addition to . . . [Full Text of this Article]

Clinical Features

Causes

Epidemiologic Features

Pathogenesis

Biology

            Growth Advantage

            Immortalization by the Action of Telomerase

            Absence of Tumor-Suppressor Genes

            Induction of Antiapoptotic Processes

            Increased Angiogenesis

            Matrix Interactions

Advances in Diagnosis

Cytologic Analysis

Histopathological Analysis

Imaging

Serum Markers

Other Blood Tests

Pulmonary-Function Tests

DNA Microarray Studies

Prognostic Factors and Staging

Advances in Treatment

Surgery

Chemotherapy

Radiotherapy

Immunotherapy

Gene Therapy

Other Therapies

Palliation

Conclusions


Source Information

From the School of Medicine and Pharmacology (B.W.S.R., R.A.L.), the Department of Respiratory Medicine (B.W.S.R.), and the Western Australian Institute for Medical Research (B.W.S.R., R.A.L.), Sir Charles Gairdner Hospital, Nedlands, Perth, Australia.

Address reprint requests to Dr. Robinson at the School of Medicine and Pharmacology, 4th Fl., G Block, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Perth 6009, Australia, or at bwsrobin@cyllene.uwa.edu.au.


Related Letters:

Malignant Mesothelioma
Pantanowitz L., Otis C. N., Muñoz A., Barceló R., López-Vivanco G., López-Ríos F., Ladanyi M., Robinson B. W.S., Lake R. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:305-307, Jan 19, 2006. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.